PREPARING FOR EMERGING VIRUSES — Sandia researchers, from left, Christine Thatcher, Jennifer Schwedler, Yooli Kim Light, Peter McIlroy and Brooke Harmon have developed a new process of screening for nanobodies that “neutralize” or disable the virus. This process represents a faster, more effective approach to developing nanobody therapies that prevent or treat viral infection.
Sandia research defends against COVID-19, prepares for future pandemics
Researchers at Sandia have created a platform for discovering, designing and engineering novel antibody countermeasures for emerging viruses. This new process of screening for nanobodies that “neutralize” or disable the virus represents a faster, more effective approach to developing nanobody therapies that prevent or treat viral infection.
Traditionally used to treat a variety of conditions, including cancer and autoimmune and inflammatory diseases, nanobodies are smaller components of conventional antibodies — a vital element of the body’s immune system that defends against disease-causing viruses or bacteria.
After screening a large, diverse library of synthetic nanobodies, Sandia researchers identified and evaluated several potent nanobodies that can protect against COVID-19. The scientists now aim to replicate this method to defend against current and future biological threats.
“The coronavirus pandemic has made evident the need for a broad range of preventive and therapeutic strategies to control diseases associated with novel viruses,” said Craig Tewell, director of Sandia’s Chemical, Biological, Radiological and Nuclear Defense and Energy Technologies Center.
With a rich history of biodefense research, Sandia helps protect the nation and the world from threats presented by bioterrorism and naturally occurring diseases, Craig said.
“With a deep understanding of how infectious disease develops and spreads, as well as how the immune system defends from infection,” Craig said, “our researchers are in a unique position to advance the creation of a wide array of disease-fighting tools, including nanobodies.”
Virologist Brooke Harmon leads Sandia’s nanobody research, a new and growing area of bioscience.
“Vaccines are very good at preventing infection, but they can take a long time to be developed and move through the regulatory process,” Brooke said. “We saw a critical need to create effective therapies that can be rapidly developed and deployed.”
Once the protein sequence, or genetic coding, of a virus has been identified, Sandia researchers have shown they can produce a nanobody-based countermeasure within 90 days. The method has not yet been tested on humans. Speeding up the discovery of neutralizing antibodies could reduce the impact of future viral outbreaks.
“Under current practice, virologists rely upon patients’ blood samples to build an antibody library that we can then screen for potential treatments. This means we have to wait, either for people to become infected or for those who are vaccinated to build an immune response,” Brooke said. “Sandia’s new method is more forward-thinking. Because we have already built a highly diverse, proprietary library, we can begin to screen for extremely potent neutralizing nanobodies as soon as the genetic coding of a virus has been identified.”
Nanobodies’ diverse attributes
Neutralizing nanobodies represents an attractive strategy, Brooke said, due to their ability to work effectively against an entire family of viruses or variants.
“We can take advantage of the fact that virus families tend to interact with immune response in the same way,” Brooke said. “This makes our treatments rapidly adaptable to all variants of a virus.”
Nanobodies are modular, meaning they can be combined with other nanobodies to increase their ability to bind to the virus or target specific tissues. Nanobodies can also be produced as smaller versions of conventional antibodies with the ability to engage the immune response.
Additionally, due to the small size of the nanobodies, they can be released into the blood and penetrate tissues more thoroughly than conventional antibodies. Nanobody therapies can also target an infection site directly, decreasing the dose needed and increasing efficacy.
Nanobodies can also be administered via aerosol, so they can be given to a patient orally or in an inhalable form. Conventional antibody treatments are less versatile and must be received through injection only.
“All of these qualities and features of nanobodies make nanobody therapies more effective than current solutions. These treatments are also easier and cheaper to manufacture,” Brooke said, “making Sandia’s method for developing and characterizing novel neutralizing antibodies an invaluable addition to the toolset for combatting the COVID-19 pandemic and future health crises.”
Sandia’s research on nanobodies for emerging viruses received national recognition in October as a recipient of a 2021 R&D 100 Award, which honors the 100 most technologically significant products and advancements in the past year.
This research also received acclamation at the 2021 National Lab Accelerator Pitch Event, where scientists present seasoned investors with business model ideas based on innovations at the DOE laboratories. A video of Sandia’s presentation at the event can be viewed here.
One role of the national laboratories is to develop innovative technologies and commercialize the underlying intellectual property through licensing agreements with companies. The labs also engage the expertise of industry and academia to further develop technology using cooperative research and development agreements. Sandia is currently exploring multiple opportunities for licensing this research and partnering with others in the bio and chemical defense, diagnostics and medical research fields.
Original Article: Neutralizing antibodies for emerging viruses
More from: Sandia National Laboratories
The Latest on: Nanobody therapies
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritison September 26, 2022 at 5:03 am
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis MoonLake announces FDA clearance for Phase 2 clinical study of the ...
- How Body-Based Therapies Alleviate Stress and Anxietyon September 23, 2022 at 3:09 pm
Innumerable studies have demonstrated that thoughts (1,2) and feelings are, indeed, reflected in the brain (3,4), so it’s no wonder that most therapies are designed to change the brain.
- Intra-Cellular Therapies: What Lies Aheadon September 20, 2022 at 12:45 pm
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Intra-Cellular Therapies' flagship product CAPLYTA (lumateperone) has significant ...
- WHO advises against use of two antibody therapies against Covidon September 20, 2022 at 11:10 am
New guidance from the World Health Organization (WHO) strongly advises against using the antibody therapies sotrovimab and casirivimab-imdevimab to treat patients with COVID-19. This guidance ...
- The WHO has advised against the use of two antibody therapies against COVID – here’s what that meanson September 17, 2022 at 1:03 am
Dr Zania Stamataki receives funding from the Medical Research Foundation, Innovate UK and BCHRF and she shares a PhD student with AstraZeneca on an iCASE MRC UKRI studentship unrelated to the ...
- WHO has advised against use of two antibody therapies against Covid – here’s what that meanson September 16, 2022 at 5:00 pm
Birmingham (UK), Sep New guidance from the World Health Organisation (WHO) strongly advises against using the antibody therapies sotrovimab and casirivimab-imdevimab to treat patients with COVID-19.
- WHO Advises Against Antibody Therapies for COVID Positive Patientson September 16, 2022 at 4:23 pm
The World Health Organisation (WHO) firmly urges against antibody medicines for COVID-19 patients, saying antibody medications rsotrovimab and casirivimab-imdevimab are not working on new variants ...
- Optimal Therapies for Treating Vitiligoon September 16, 2022 at 3:14 pm
Jeffrey D. Dunn, PharmD, MBA: We’ve talked about topical steroids, topical calcineurin inhibitors, and light therapy. There are some other things that are used, such as systemic ...
- WHO 'strongly advises against' use of antibody therapies as COVID treatmenton September 16, 2022 at 8:40 am
Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete.
- Intratumoral Cancer Therapies Market is expected to grow at a significant CAGR by 2032 | DelveInsighton September 15, 2022 at 1:06 pm
The Intratumoral Cancer Therapies market is expected to show positive growth in the forecast period (2022–2032) due to the increased prevalence, randomized, controlled non-crossover trials with ...
via Bing News
The Latest on: Nanobody therapies
via Google News